人工智能在帕金森病治疗中的研究进展

doi:10.3969/j.issn.1003-9198.2025.11.003

摘要/Abstract

摘要： PD是以黑质-纹状体多巴胺能通路变性为主要病理改变的神经系统变性疾病,给病人带来极大痛苦。PD的传统治疗方法存在局限性。近年来,人工智能(artificial intelligence,AI)在PD治疗中展现出巨大潜力。本综述系统性地阐述AI在PD治疗中的多方面应用,包括药物治疗优化、手术治疗参数调整、康复与症状管理以及非运动症状监测等。未来需通过多维度数据融合和模型优化,进一步提升AI在PD治疗中的精准性和可及性,为临床治疗提供新思路。

关键词: 帕金森病, 治疗, 人工智能

Abstract: Parkinson’s disease (PD) is a neurodegenerative disorder characterized by the degeneration of the dopaminergic pathway in the substantia-striatal region, which brings great suffering to patients, and traditional treatment methods have limitations. In recent years, artificial intelligence has shown great potential in the treatment of PD. In this review, we systematically elaborate on the multi-faceted application of artificial intelligence in the treatment of PD through a comprehensive analysis of the existing literature, including drug treatment optimization, surgical treatment parameter adjustment, rehabilitation and symptom management, and non-motor symptom monitoring. In the future, multi-dimensional data fusion and model optimization are needed to further enhance the accuracy and accessibility of artificial intelligence in the treatment of Parkinson’s disease, providing new ideas for clinical treatment.

Key words: Parkinson’s disease, therapy, artificial intelligence

中图分类号:

王冠群, 王新平, 袁永胜. 人工智能在帕金森病治疗中的研究进展[J]. 实用老年医学, 2025, 39(11): 1088-1092.

WANG Guanqun, WANG Xinping, YUAN Yongsheng. Research advances of artificial intelligence in the treatment of Parkinson’s disease[J]. Practical Geriatrics, 2025, 39(11): 1088-1092.

参考文献

[1] AARSLAND D, BATZU L, HALLIDAY G M, et al. Parkinson disease-associated cognitive impairment[J]. Nat Rev Dis Primers, 2021, 7(1): 47.
[2] MACLAGAN L C, VISANJI N P, CHENG Y, et al. Identifying drugs with disease-modifying potential in Parkinson’s disease using artificial intelligence and pharmacoepidemiology[J]. Pharmacoepidemiol Drug Saf, 2020, 29(8): 864-872.
[3] XU T, DONG W, LIU J, et al. Disease burden of Parkinson’s disease in China and its provinces from 1990 to 2021: findings from the global burden of disease study 2021[J]. Lancet Reg Health West Pac, 2024, 46: 101078.
[4] TOLOSA E, GARRIDO A, SCHOLZ S W, et al. Challenges in the diagnosis of Parkinson’s disease[J]. Lancet Neurol, 2021, 20(5): 385-397.
[5] ARMSTRONG M J, OKUN M S. Diagnosis and treatment of Parkinson disease: a review[J]. JAMA, 2020, 323(6): 548-560.
[6] KWON D K, KWATRA M, WANG J, et al. Levodopa-induced dyskinesia in Parkinson’s disease: pathogenesis and emerging treatment strategies[J]. Cells, 2022, 11(23): 3736.
[7] GUTOWSKI T, ANTKIEWICZ R, SZLUFIK S. Machine learning with optimization to create medicine intake schedules for Parkinson’s disease patients[J]. PLoS One, 2023, 18(10): e0293123.
[8] WU K M, XU Q H, LIU Y Q, et al. Neuronal FAM171A2 mediates α-synuclein fibril uptake and drives Parkinson’s disease[J]. Science, 2025, 387(6736): 892-900.
[9] HARIZ M, BLOMSTEDT P. Deep brain stimulation for Parkinson’s disease[J]. J Intern Med, 2022, 292(5): 764-778.
[10] ZHOU T, XU W, SHI W. Investigation of the mechanism of action of deep brain stimulation for the treatment of Parkinson’s disease[J]. Cogn Neurodyn, 2024, 18(2): 581-595.
[11] NEUMANN W J, TURNER R S, BLANKERTZ B, et al. Toward electrophysiology-based intelligent adaptive deep brain stimulation for movement disorders[J]. Neurotherapeutics, 2019, 16(1): 105-118.
[12] ROEDIGER J, DEMBEK T A, ACHTZEHN J, et al. Automated deep brain stimulation programming based on electrode location: a randomised, crossover trial using a data-driven algorithm[J]. Lancet Digit Health, 2023, 5(2): e59-e70.
[13] GOETZ C G, TILLEY B C, SHAFTMAN S R, et al. Movement disorder society-sponsored revision of the unified Parkinson’s disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results[J]. Mov Disord, 2008, 23(15): 2129-2170.
[14] YANG Y, YUAN Y, ZHANG G, et al. Artificial intelligence-enabled detection and assessment of Parkinson’s disease using nocturnal breathing signals[J]. Nat Med, 2022, 28(10): 2207-2215.
[15] PURRER V, POHL E, LUECKEL J M, et al. Artificial-intelligence-based MRI brain volumetry in patients with essential tremor and tremor-dominant Parkinson’s disease[J]. Brain Commun, 2023, 5(6): fcad271.
[16] LI C, HUI D, WU F, et al. Automatic diagnosis of Parkinson’s disease using artificial intelligence base on routine T1-weighted MRI[J]. Front Med, 2024, 10: 1303501.
[17] REDDY S, GIRI D, PATEL R. Artificial intelligence diagnosis of Parkinson’s disease from MRI scans[J]. Cureus, 2024, 16(4): e58841.
[18] BURTSCHER J, MORAUD E M, MALATESTA D, et al. Exercise and gait/movement analyses in treatment and diagnosis of Parkinson’s disease[J]. Ageing Res Rev, 2024, 93: 102147.
[19] ILEŞAN R R, CORDOŞ C G, MIHÄILÄ L I, et al. Proof of concept in artificial-intelligence-based wearable gait monitoring for Parkinson’s disease management optimization[J]. Biosensors, 2022, 12(4): 189.
[20] 张立新, 白定群, 白玉龙,等. 下肢康复机器人临床应用专家共识[J]. 康复学报,2023,33(5):383-396.
[21] KWON S H, PARK J K, KOH Y H. A systematic review and meta-analysis on the effect of virtual reality-based rehabilitation for people with Parkinson’s disease[J]. J Neuroeng Rehabil, 2023, 20(1): 94.
[22] KASHIF M, AHMAD A, BANDPEI M A M, et al. Combined effects of virtual reality techniques and motor imagery on balance, motor function and activities of daily living in patients with Parkinson’s disease: a randomized controlled trial[J]. BMC Geriatr, 2022, 22(1): 381.
[23] GULCAN K, GUCLU-GUNDUZ A, YASAR E, et al. The effects of augmented and virtual reality gait training on balance and gait in patients with Parkinson’s disease[J]. Acta Neurol Belg, 2023, 123(5): 1917-1925.
[24] SAXON M, TRIPATHI A, JIAO Y, et al. Robust estimation of hypernasality in dysarthria with acoustic model likelihood features[J]. IEEE/ACM Trans Audio Speech Lang Process, 2020, 28: 2511-2522.
[25] KUMAR R, TRIPATHY M, KUMAR N, et al. Management of Parkinson’s disease dysarthria: can artificial intelligence provide the solution?[J]. Ann Indian Acad Neurol, 2022, 25(5): 810-816.
[26] 韦朝霞,李丽华,罗庆禄,等. 人工智能在帕金森病构音障碍研究中的应用进展[J]. 中华神经科杂志,2024,57(11):1259-1263.
[27] AMATO F, BORZÌ L, OLMO G, et al. An algorithm for Parkinson’s disease speech classification based on isolated words analysis[J]. Health Inf Sci Syst, 2021, 9(1): 32.
[28] 刘培培, 巫嘉陵. 基于视频信息的帕金森病智能辅助诊断与治疗进展[J]. 中国现代神经疾病杂志, 2023, 23(1): 35-39.
[29] KANG M G, YUN S J, SHIN H I, et al. Effects of robot-assisted gait training in patients with Parkinson’s disease: study protocol for a randomized controlled trial[J]. Trials, 2019, 20(1): 15.
[30] OMBERG L, CHAIBUB NETO E, PERUMAL T M, et al. Remote smartphone monitoring of Parkinson’s disease and individual response to therapy[J]. Nat Biotechnol, 2022, 40(4): 480-487.
[31] XU X, ZENG Z, QI Y, et al. Remote video-based outcome measures of patients with Parkinson’s disease after deep brain stimulation using smartphones: a pilot study[J]. Neurosurg Focus, 2021, 51(5): E2.
[32] BOUGEA A, ANGELOPOULOU E. Non-motor disorders in parkinson disease and other parkinsonian syndromes[J]. Medicina, 2024, 60(2): 309.
[33] MEINERT E, MILNE-IVES M, CHAUDHURI K R, et al. The impact of a digital artificial intelligence system on the monitoring and self-management of nonmotor symptoms in people with parkinson disease: proposal for a phase 1 implementation study[J]. JMIR Res Protoc, 2022, 11(9): e40317.
[34] JANSSEN DAALEN J M, VAN DEN BERGH R, PRINS E M, et al. Digital biomarkers for non-motor symptoms in Parkinson’s disease: the state of the art[J]. NPJ Digit Med, 2024, 7(1): 186.
[35] ALTHAM C, ZHANG H, PEREIRA E. Machine learning for the detection and diagnosis of cognitive impairment in Parkinson’s disease: a systematic review[J]. PLoS One, 2024, 19(5): e0303644.
[36] WU Y, CHENG Y, XIAO Y, et al. The role of machine learning in cognitive impairment in parkinson disease: systematic review and meta-analysis[J]. J Med Internet Res, 2025, 27: e59649.
[37] GODOY C A, MIELE F, MÄKITIE L, et al. Attitudes toward the adoption of remote patient monitoring and artificial intelligence in Parkinson’s disease management: perspectives of patients and neurologists[J]. Patient, 2024, 17(3): 275-285.